Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury

Exclusion Criteria

• •Age \< 18 years
• •Signs of hypovolemia including systolic BP \< 90 mmHg
• •Signs of liver disease including jaundice and ascites
• •* AST \> 35 units/L
• •* ALT \> 35 units/L
• •Signs of renal disease including history of dialysis
• •* Serum creatinine \> 1.5 mg/dL
• •* BUN \> 20 mg/dL range
• •Baseline serum sodium \>/= 145 mEq/L
• •Pregnant or lactating females
• •Concomitant use of digoxin, ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, simvastatin and lovastatin
• •Presentation to the tertiary care hospital \> 24 hours post-injury
• •Multi-system traumatic injuries
• •Diabetes Insipidus
• •Anticipation of diagnosis compatible with brain death, or no expectation of survival with 48 hours.